Dacogen(TM) Data Presented at the 45th Annual Meeting of the American Society of Hematology (ASH)
December 05 2003 - 9:15AM
PR Newswire (US)
Dacogen(TM) Data Presented at the 45th Annual Meeting of the
American Society of Hematology (ASH) 18 abstracts and presentations
describe clinical and preclinical data DUBLIN, Calif., Dec. 5
/PRNewswire-FirstCall/ -- SuperGen, Inc. announced today that a
variety of preclinical and clinical data from studies involving the
investigational anticancer compound Dacogen(TM) (decitabine for
injection) will be presented at the 45th Annual Meeting of the
American Society of Hematology (ASH) in San Diego. 18 abstracts and
presentations of both clinical and preclinical studies involving
Dacogen were published in the November 16, 2003 issue of Blood
(volume 102, issue 11), all but one of which will be presented
during the meeting. These abstract and presentations include:
Clinical Data: -- #58 - Effective Combination Treatment with
Imatinib (Gleevec(TM)) Requires Residual Bcr-Abl-Induction in
Imatinib-resistant Cell Lines: Oral Session -- #1541 - LDH is an
Important Risk Factor to Predict Survival in Patients with MDS
Treated with 5-aza-2'-deoxycytidine (decitabine). Poster Session --
#1551 - Karyotypic Stability or Chromosomal Evolution during
Treatment with a DNA Demeythylating Agent? A serial Study of
Patients with the Myelodysplastic Syndrome. Poster session -- #3383
- Phase I Study of a Imatinib and Tripifarnib (Zarnestra(TM),
R115777) in Patients with Chronic Myeloid Leukemia in Chronic Phase
Refractory to Imatinib. Poster Session -- #3385 - Phase II Study of
5-aza-2'-deoxycytidine (decitabine) in Patients with Philadelphia
Chromosome Positive Chronic Myelogenous Leukemia (CML) Resistant or
Intolerant to Imatinib Mesylate (Gleevec(TM)). Poster Session
Preclinical Data: -- #947 - Globin Promoter Methyl CpG Density is a
key Factor in ?-Globin Gene Silencing. Poster Session -- #765 -
AML1/ETO Associates with DNA Methyltransferase 1 (DNMT1) in
Inducing Transcriptional Repression of the AML1-Target Gene
Interleukin-3 (IL-3): Oral Session -- #775 - Activation of the
Silenced MLL (ALL-1) Wild-Type Allele in Acute Myeloid Leukemia
(AML) with the MLL Partial Tandem Duplication Results in
Enhancement of Cell Death: Oral Session -- #1412 - Combined Effect
of Phenylbutyrate and 5-aza-2'-deoxycytidine (decitabine) in
t(8;21) AML Leukemia Cells in Vitro and In Vivo: Poster Session --
#2295 - Preclinical Studies of the Combination of the
Hypomethylating Agent 5-aza-2'-Deoxycytidine (Decitabine) and the
Histone Deacetylase Inhibitor (HDI) Valproic Acid (VPA) in Leukemic
Cell Systems. Poster Session -- #2315 - Characterization and DNA
Methyltransferase Inhibitor Treatment of Primary Murine T/NK Acute
Lymphoblastic Leukemia (ALL). Poster Session -- #2403 - SAHA, a
Histone Deacetylase Inhibitor, Induces Apoptosis in Cutaneous T
Cell Lymphoma Cells and is Synergistic with 5-Aza-2'- Deoxtcytidine
(decitabine). Poster Session -- #2404 - Decitabine Up-Regulates the
Expression of the Cancer-Associate Prame Antigen in Early Chronic
Phase CML Cells. Poster Session -- #2514 - Direct and Indirect
Effects of Decitabine on Gene Expression in Burkitt's Lymphoma
(EBV+) and Human Myeloma (EBV-) Cell Lines. Poster Session -- #2574
- Ex-Vivo Culture Rescues Radioprotective and Long-Term
Repopulating Stem and Progenitor Cells Following Harvest from
Lethally Irradiated Animals. Poster Session -- #3163 - Role of
Promoter Methylation in Regulation of the Heparanase Gene. Poster
Session -- #3167 - Exposure of Human AML Cells to
5-Aza-2'-Deoxycytidine (decitabine) Alone or in Combination with
Trichostatin A Induces p21CIP1 in the Absence of Dense Promoter
Methylation. Poster Session -- #4571 - Impact of 5-azacytidine and
2'-deoxy-5-azacytidine (decitabine) on Histone Acetylation and
Expression of the Non-Methylated p21WAF1/CIP1 Gene. Publication
"The scope and depth of the scientific and clinical interest in
Dacogen continues to strengthen our belief that this agent could
become an important tool in the treatment of a variety of
hematological conditions," said Craig Rosenfeld, M.D., Senior Vice
President and Chief Scientific Officer of SuperGen. The primary
mechanism of action for Dacogen in cancer is thought to be
modification of aberrant DNA methylation, a major mechanism for
regulating gene expression and reversing resistance to chemotherapy
treatment. Based in Dublin, California, SuperGen is a
pharmaceutical company dedicated to the acquisition, rapid
development and commercialization of therapeutic anticancer
products. The Company's website can be reached at
http://www.supergen.com/. This press release contains
"forward-looking" statements within the meaning of section 21A of
the Securities Act of 1933, as amended, and section 21E of the
Securities Exchange Act of 1934, as amended, and is subject to the
safe harbor created thereby. Such forward-looking statements
include statements related to our expectations regarding Dacogen as
a single agent and in combination with other chemotherapeutic drugs
in the treatment of various hematological conditions. The success
of such product could differ materially from those discussed in the
forward-looking statements as a result of known and unknown risk
factors and uncertainties. Such factors include, but are not
limited to: risks and uncertainties related to initiating,
conducting and completing clinical trials, whether Dacogen will
demonstrate any clinical benefit in any hematological conditions,
and whether the company will submit Dacogen for regulatory approval
for any indications, or if the drug will ever be approved or reach
the market. References made to the discussion of the risk factors
are detailed in the company's filing with the Securities and
Exchange Commission including the report on Form 10-Q for the
quarter ended September 30, 2003. These forward-looking statements
are made only as of the date hereof, and we disclaim any obligation
to update or revise the information contained in any such
forward-looking statements, whether as a result of new information,
future events or otherwise. Contact: Tim Enns, Vice President,
Investor Relations & Business Development, SuperGen, Inc.,
800-353-1075, ext. 111 DATASOURCE: SuperGen, Inc. CONTACT: Tim
Enns, Vice President, Investor Relations & Business
Development, SuperGen, Inc., 800-353-1075, ext. 111 Web site:
http://www.supergen.com/
Copyright